Loading data for NERV — first visit, this takes a few seconds.

알림

Minerva Neurosciences Inc... (NERV)

NasdaqCM: NERV · 실시간 가격 · USD

3.92

-0.40 (-9.26%)

종가 기준: Aug 20, 2026, 5:30 PM

-9.26% (1D)

데이터 없음

매수호가	3.19
시가총액	226.32M
매출 (ttm)	n/a
순이익 (ttm)	-394.35M
베타	-0.11
EPS (ttm)	-36.12
P/E (ttm)	n/a
선행 P/E	-11.29
P/B (ttm)	-1.05
P/S (ttm)	n/a
Earnings Date	Aug 5, 2025

매도호가	5.41
거래량	138,129
평균 거래량 (20일)	225,700
시가	4.31
전일 종가	4.32
일중 범위	3.90 - 4.56
52주 범위	1.76 - 12.46
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

NERV 소개

Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts....

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Jul 1, 2014

직원 수 7

상장 거래소 NasdaqCM

티커 NERV

웹사이트 https://www.minervaneurosciences.com

전체 기업 정보

재무 실적

2025년 Minerva Neurosciences의 매출은 0로, 전년 0 대비 undefined% 증가했습니다. 순이익은 -293.42M로, -20,492.68% 감소했습니다.

재무제표

어닝 서프라이즈

Minerva Neurosciences가 Aug 7, 2026에 분기 실적을 발표했습니다:

매출 $0 예상치 하회 $0, 및 NaN% 전년 대비 성장.

EPS -0.17 예상치 하회 -0.16, 및 60.47% 전년 대비 성장.

다음 실적 발표

Minerva Neurosciences Inc.의 실적 발표 예정일은 Aug 5, 2025, 장 시작 전입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

3개월 전 · Zacks

All You Need to Know About Minerva Neurosciences (NERV) Rating Upgrade to Buy

Minerva Neurosciences (NERV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

3개월 전 · Zacks

Minerva Neurosciences (NERV) Loses 37.5% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

The heavy selling pressure might have exhausted for Minerva Neurosciences (NERV) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Stre...

5개월 전 · MarketBeat

Minerva Neurosciences Touts Roluperidone Data, FDA-Aligned Trial Plan for Schizophrenia Symptoms

Minerva Neurosciences (NASDAQ:NERV) provided an update on its development program for roluperidone, which the company described as a potential first treatment option aimed at the negative symptoms of ...

5개월 전 · Associated Press Finance

Minerva Neurosciences: Q4 Earnings Snapshot

BURLINGTON, Mass. AP) — Minerva Neurosciences Inc. NERV) on Wednesday reported a loss of $283.7 million in its fourth quarter.

6개월 전 · Simply Wall St.

Institutions profited after Minerva Neurosciences, Inc.'s (NASDAQ:NERV) market cap rose US$27m last week but individual investors profited the most

Key Insights Minerva Neurosciences' significant individual investors ownership suggests that the key decisions are...

2 페이지 중 1

Minerva Neurosciences Inc... (NERV)